Newsletter Subscription

Enter Name and Email

08 July 2011 - Launch of Neurolixis Inc.: biopharmaceutical start-up company

In the current climate of pharmaceutical industry restructuring, considerable opportunities exist for innovation in the areas of neuropsychiatry and neurology. This is why Adrian Newman-Tancredi Ph.D., together with other experienced neuroscience researchers, has founded Neurolixis Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of human central nervous system diseases including depression, schizophrenia, Parkinson's disease, ADHD and autism.
Adrian will direct drug discovery and neuropharmacology studies and evaluate licensing candidates.

For further information on this exciting new venture, or if you are interested in risk-sharing collaborations, visit www.neurolixis.com.